Compare TSLX & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSLX | EVO |
|---|---|---|
| Founded | 2010 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 778.3M |
| IPO Year | 2011 | 2007 |
| Metric | TSLX | EVO |
|---|---|---|
| Price | $18.77 | $1.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $21.61 | $7.00 |
| AVG Volume (30 Days) | ★ 474.4K | 47.3K |
| Earning Date | 05-05-2026 | 04-08-2026 |
| Dividend Yield | ★ 10.82% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | $1.20 | $10.05 |
| P/E Ratio | $127.80 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.04 | $1.90 |
| 52 Week High | $24.79 | $4.27 |
| Indicator | TSLX | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 62.44 | 38.88 |
| Support Level | $17.20 | $1.90 |
| Resistance Level | $19.75 | $3.84 |
| Average True Range (ATR) | 0.46 | 0.05 |
| MACD | 0.13 | 0.04 |
| Stochastic Oscillator | 80.00 | 21.31 |
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. The company partners with other companies across a variety of industries and provides creative solutions with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.